Quick Facts
  • Primary Location:
    Tennessee Oncology
  • Expertise:
    Gastrointestinal Malignancies
    HIPEC
  • Speciality:
    Surgical Oncology
  • Gender:
    Male
  • Language:
    English
  • Med School:
    Chicago College of Osteopathic Medicine, Midwestern University

Get to Know Dr. Jeremiah L. Deneve

Dr. Jeremiah Deneve is a surgical oncologist who helped start a program using cytoreduction and hyperthermic intraperitoneal chemotherapy, also known as HIPEC, at the University of Tennessee Health Science Center in Memphis.

The combination treatment has dramatically improved the prognosis of patients with various abdominal malignancies, including mesothelioma, a rare cancer once considered almost untreatable.

It is an arduous procedure that first involves removing all visible tumor growth throughout the abdominal cavity.

It is followed by the direct delivery of a heated, high-dose chemotherapy solution, which is circulated for up to 90 minutes before it is drained and the abdomen is closed.

The second phase is designed to kill any tumor cells that evaded the surgeon.

Deneve also treats melanoma, other soft tissue sarcomas and pancreatic and gastrointestinal cancers.

He is part of Methodist LeBonheur Healthcare. He sees patients at University of Tennessee Methodist Physicians Surgical Oncology.

Contact Jeremiah L. Deneve

Specialties of Dr. Jeremiah Deneve

  • Peritoneal mesothelioma
  • Gastrointestinal malignancies
  • Melanoma
  • HIPEC
  • Pancreatic cancer

Dr. Jeremiah Deneve’s Experience and Medical Education

  • University of Tennessee Health Science Center
  • Moffitt Cancer Center (Fellowship)
  • Emory University School of Medicine (Fellowship)
  • Emory University Department of Surgery (Residency)
  • Chicago College of Osteopathic Medicine, Midwestern University (M.D.)

Awards and Certifications

  • American Board of Surgery
  • Compassionate Doctor Certification
  • Patients Choice Award

Mesothelioma Clinical Trials Under Dr. Jeremiah Deneve

  • A randomized clinical trial studying the surgical or nonsurgical management of quality of life issues in treating patients with intra-abdominal cancers, such as peritoneal mesothelioma, and bowel obstruction.

Publications of Dr. Jeremiah Deneve

  • Lewis, R. et al. (2019, December 5). Outcomes Following Resection of Hepatocellular Carcinoma in the Absence of Cirrhosis. Journal of Gastrointestinal Cancer.
  • Deneve, J. et al. (2018, April 9). Early experience with cytoreduction and hyperthermic intraperitoneal chemotherapy at a newly developed center for peritoneal malignancy. Journal of Gastrointestinal Oncology.
  • Stiles, Z. et al. (2018, March 19). The impact of unplanned conversion to an open procedure during minimally invasive pancreatectomy. Journal of Surgical Research.
  • Deneve, D. et al. (2015, June 15). Chemosaturation with percutaneous hepatic perfusion for unresectable isolated hepatic metastases from sarcoma. Cardiovascular Interventional Radiology.

Lab technician using a microscope in a lab
COVID-19 and Mesothelioma Presentation
United States one-hundred-dollar bills
Access More than $32 Billion in Trust Funds
Technician documenting notes in a lab
Find Active Mesothelioma Clinical Trials

  •  
  •  
  •  
Tell us what you think
Did this article help you?
How did this article help you?
What about this article isn’t helpful for you?
Did this article help you?

Thank you for your feedback. Would you like to speak with a Patient Advocate?